NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

PolyModels Hub raises £1.1M to revolutionise pharma process development

PolyModels Hub founders
Picture credits: PolyModels Hub

PolyModels Hub, a London-based biotech software startup, has raised £1.1 million in seed funding. The investment round was led by Marathon Venture Capital, a seed-stage venture capital fund. 

This follows the investment in similar startups such as Skycell, which builds temperature-controlled containers for pharma goods transport, and UK-based same-day delivery service Phlo.

Funds utilisation

The round will enable the team to expand, accelerating an ambitious product roadmap and meeting the rapidly growing demand for their innovative solution.

Alex Alexakis, investor at Marathon Venture Capital added: “The pharma industry is being revolutionised by modern technologies including AI, biotechnology, and robotics. Yet, pharma process development, which is a critical part of taking a drug product to market, is still driven by the empirical knowledge of scientists and relies on paper-based systems and manual processes. PolyModels Hub brings a rare mix of chemical and software engineering expertise to digitalise pharma process development and help pharma deliver breakthrough therapies faster to the growing and ageing population. We are excited to work together and help bring their vision forward.”

The challenge!

Developing breakthrough therapies for patients is a major societal challenge. Sophisticated drug processes are needed for complex therapeutic modalities, but maintaining high-quality standards is crucial. Traditionally, R&D costs per molecule have increased, but digital technology and data integration offer hope for reversing this trend. 

Digital models in process design are transforming R&D and are being progressively adopted. However, many pharma organisations find these tools difficult to manage and understand. Choosing the right modelling approach is especially challenging when experimental data is limited. 

PolyModels Hub tackles this challenge with its comprehensive digital platform designed to revolutionise pharma process development. 

What does the company do?

The biotech software startup was founded in 2022 by Antonio Benedetti, Harry Christodoulou, and Antonio Yankey in London. The company brings unique chemical and software engineering expertise and has partnered with leading pharmaceutical companies to digitally design and run in-silico simulations for new and existing medicines. 

These simulations directly impact key decisions on the quality attributes of drugs, accelerating time to market and saving millions in process development costs. It aims to build the digital backbone for pharma process development, helping scientists conduct research, collaborate, build, and manage their drug portfolios all-in-one platform.

In a short time, they have also managed to build an audience of pharma researchers through the community part of their platform, where scientists can highlight and discuss the latest tools of the trade, finding, and rating papers with scientific models and pharma process development best practices.

The company is on a journey to empower scientists with AI tools to model, simulate, and get access to insights across all steps and protocols followed to turn chemical compounds into safe drug products – all inside a collaborative platform made for pharma.

Revolutionises pharma process development 

ModelFlow, its digital platform seamlessly integrates models, scientific data, and insights into a single, cohesive product. This platform shifts the focus to advancing a company’s medicine portfolio through regulatory and business milestones by offering a robust solution for project management and the maximisation of digital tools.

With ModelFlow, scientists, digital teams, and pharma leaders can collaborate effectively, building and managing every aspect of how models should create significant impact and value in developing new drugs or optimising existing ones. By leveraging the founders’ combined expertise, ModelFlow delivers a streamlined tech-enabled library of model-based workflows that unites essential data, information, model files, web app deployment, and insights into a simple yet highly effective tool.

“Developing a drug remains an expensive and time-consuming process. Unlike other industries, product development in pharmaceuticals relies heavily on numerous experiments with minimal knowledge transfer from past products, driven by the expertise and know-how of scientists. We have witnessed first-hand the inefficiencies of traditional drug development, as well as the growing desire and business need to transform this field. Our vision for PolyModels Hub is to revolutionise how scientists, digital teams, and senior stakeholders collaborate to accelerate development efforts and bring breakthrough therapies to market faster than ever. With today’s advanced technology, supportive business context, and favourable regulatory framework, we believe now is the perfect time to realise this vision.” added Antonio Benedetti, co-founder & CEO.

Harry Christodoulou, co-founder & Director of Modelling & Science, commented: “Modelling and simulations in the pharmaceutical industry are becoming increasingly popular, with entire teams now focusing on digitalizing their processes using advanced techniques, ranging from AI to Computational Fluid Dynamics. These digital solutions require a unique central platform where they can create tangible value for scientific and modelling projects in a systematic manner. This is precisely why we founded PolyModels Hub and developed our product, ModelFlow.”

“Our next steps involve significantly enhancing our platform, rolling out advanced modelling and simulation tools, integrating the best software and technology components into a simple and intuitive platform. Additionally, our AI layer will recommend the optimal tools for each task, ensuring efficiency and precision. We are also committed to expanding our team with top-tier talent to support our ambitious goals and drive the digital transformation in pharma process development,” mentioned Antonio Yankey, Co-founder & Director of Tech & Product. 

What do we think about the company?

PolyModels Hub is revolutionising pharma process development with its comprehensive digital platform, ModelFlow. By integrating AI, simulations, and data insights, they streamline drug development, reducing costs and accelerating time to market. Its unique blend of chemical and software engineering expertise addresses inefficiencies in traditional methods, fostering collaboration among scientists and pharma leaders. With substantial funding and strategic partnerships, PolyModels Hub is poised to significantly impact the pharmaceutical industry.

Related Posts
Total
0
Share

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you